Regeneron Pharmaceuticals, Inc. Share Price

Equities

REGN

US75886F1075

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 10/05/2024 BST 5-day change 1st Jan Change
973.8 USD +0.60% Intraday chart for Regeneron Pharmaceuticals, Inc. +1.76% +10.87%
Sales 2024 * 13.85B 1,106B Sales 2025 * 14.95B 1,194B Capitalization 105B 8,391B
Net income 2024 * 4.06B 324B Net income 2025 * 4.47B 357B EV / Sales 2024 * 6.93 x
Net cash position 2024 * 9.06B 724B Net cash position 2025 * 14.79B 1,181B EV / Sales 2025 * 6.04 x
P/E ratio 2024 *
27.6 x
P/E ratio 2025 *
24.9 x
Employees 13,677
Yield 2024 *
-
Yield 2025 *
-
Free-Float 78.34%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.60%
1 week+1.76%
Current month+9.33%
1 month+4.02%
3 months+2.14%
6 months+21.89%
Current year+10.87%
More quotes
1 week
950.27
Extreme 950.27
979.98
1 month
875.23
Extreme 875.225
979.98
Current year
871.39
Extreme 871.39
998.33
1 year
684.81
Extreme 684.805
998.33
3 years
492.13
Extreme 492.13
998.33
5 years
271.37
Extreme 271.37
998.33
10 years
269.50
Extreme 269.5
998.33
More quotes
Managers TitleAgeSince
Founder 64 07/01/88
Chief Executive Officer 71 07/01/88
Director of Finance/CFO 54 31/12/02
Members of the board TitleAgeSince
Director/Board Member 71 11/11/10
Chief Executive Officer 71 07/01/88
Director/Board Member 82 31/05/91
More insiders
Date Price Change Volume
10/05/24 973.8 +0.60% 351,356
09/05/24 968 +1.28% 281,949
08/05/24 955.8 -1.46% 424,925
07/05/24 970 +1.18% 362,320
06/05/24 958.6 +0.17% 352,000

Delayed Quote Nasdaq, May 10, 2024 at 09:00 pm

More quotes
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from product sales (56.6%); - revenues from collaboration agreements (40.4%): collaboration with Sanofi (58.1% of revenues), Bayer (29.1%) and Roche (12.8%); - other (3%): primarily revenues from sales of technology licenses and subcontracted research services. At the end of 2022, the group had a portfolio of approximately 35 products in clinical development.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
973.8 USD
Average target price
1,028 USD
Spread / Average Target
+5.53%
Consensus